Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Aug 1.

Published in final edited form as: Adv Healthc Mater. 2016 Apr 25;5(15):1868–1873. doi: 10.1002/adhm.201600230

Cell viability of free PTX (■), mPEG-poly(TMC-PTX_1.4) ( ), mPEG-poly(TMC-PTX_2.7) ( ), mPEG-polyPTX_5.8 ( ) and mPEG-polyPTX_8.7 ( ) against (a) HT-29, (b) MDA-MB-231 and (c) PANC-1 cells, respectively. The cells were incubated for 72 h and the cell viability (in %) is normalized against untreated cells in the same experiment. (d) Plot of mean body weight change of mice with a dose escalation trial of mPEG-PPTX_8.7 as a function of time. Points represent the mean ± SD (n=3 to 4). (e) Tumour volume up to day 100 (mean ± SD; n = 5). PBS (■), 25 mg kg⁻¹ of free PTX ( ), and mPEG-PPTX_8.7 at dose of 25 ( ), 75 ( ), and 225 ( ) mg PTX equivalent per kilogram BW were systemically administered via intravenous tail vein injection on day 0, 6 and 12, respectively. * indicates P < 0.001 (One-tailed heteroscedastic t-test). (f) Cumulative survival of mice (Kaplan–Meier).

Inline graphic — Cell viability of free PTX (■), mPEG-poly(TMC-PTX_1.4) ( ), mPEG-poly(TMC-PTX_2.7) ( ), mPEG-polyPTX_5.8 ( ) and mPEG-polyPTX_8.7 ( ) against (a) HT-29, (b) MDA-MB-231 and (c) PANC-1 cells, respectively. The cells were incubated for 72 h and the cell viability (in %) is normalized against untreated cells in the same experiment. (d) Plot of mean body weight change of mice with a dose escalation trial of mPEG-PPTX_8.7 as a function of time. Points represent the mean ± SD (n=3 to 4). (e) Tumour volume up to day 100 (mean ± SD; n = 5). PBS (■), 25 mg kg⁻¹ of free PTX ( ), and mPEG-PPTX_8.7 at dose of 25 ( ), 75 ( ), and 225 ( ) mg PTX equivalent per kilogram BW were systemically administered via intravenous tail vein injection on day 0, 6 and 12, respectively. * indicates P < 0.001 (One-tailed heteroscedastic t-test). (f) Cumulative survival of mice (Kaplan–Meier).